Clinical Trial

Destination Therapy Post Approval Study

Study acronym: DT PAS
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Medtronic is sponsoring the HeartWare™ HVAD™ Destination Therapy (DT) Post Approval Study (PAS) to further confirm safety and effectiveness of the HeartWare Ventricular Assist Device System (HVAD System) when used as intended, in "real-world" clinical practice. The Destination Therapy Post Approval Study (DT PAS) is conducted within Medtronic's Product Surveillance Platform.
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2018-09-20; most recent amendment 2025-08-18.
Status change: Recruiting → Active, Not Recruiting 2021-05-03
Status change: Not Yet Recruiting → Recruiting 2018-11-21
Trial Details
NCT Number NCT03681210
Lead Sponsor Medtronic Cardiac Rhythm and Heart Failure
Conditions Chronic Heart Failure
Enrollment 300 participants
Start Date 2018-10-31
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-22